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1. Introduction 
1.1 Cutaneous sarcoidosis  
Sarcoidosis is a multisystem  granulomatosis disease of unknown etiology, characterized 
pathologically by noncaseating granulomas in involved tissues1,2. It mainly involves the 
lungs but may also be associated with systemic manifestations3. The disease most commonly 
affects the lungs, lymph nodes, liver, spleen, phalangeal bones, parotid glands, eyes, and 
skin4. Skin involvement rarely causes significant morbidity or mortality. However, it can 
adversely affaect a patient’s quality of life by causing cosmetic impairment 5. 
1.2 History 
Sarcoidosis is first described by Sir Jonathan Hutchinson in 18756. In 1889 the dermatologist 
Besnier described lupus pernio (sarcoidosis of the face) as a variant of cutaneous sarcoidosis. 
In 1899, Boeck described benign sarcoid and miliary lupoid 4,6. 
1.3 Epidemiology 
Sarcoidosis occurs worldwide and affects all ages and races. Disease onset is most often in 
the third decade of life, although a smaller second peak occurs in people older than 50 
years7. 
1.4 Etiology and pathogenesis 
The cause of sarcoidosis is unknown. It has been suggested that sarcoidosis is a 
hypersensitivity reaction caused by prolonged exposure to a spesisic antigen8. Although a 
spesific antigen has not yet been identified for sarcoidosis , the immune response which 
leads to recognizable clinical lesions and functional impairment is of the type 1 
variety:elevated IFN gama , IL-2, and Th1 immune regulatory monokine IL2 characterize 
sarkoidosis9. Although mycobacteria have not been identified with traditional methods, 
mycobacterial DNA has been found in sarcoidal lesions10. Infectious agents such as 
mycobacteria, propionibacterium acnes and Chlamydia have been associated with 
sarcoidosis11. The etiologic role of various chemicals and metals such as beryllium, 
aluminium, zirconium, and titanium has also been debated. Treatment with interferons 
can cause a variety of inflammatory conditions, including sarcoidosis4. Genetic 
susceptibility to sarcoidosis has been associated with HLA -1, HLA-B8, and HLA-DR3 
alleles6. 
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1.5 Cutaneous lesions 
Sarcoidosis involves so many organs that it is diffucult to describe all the features. About 40-
50% of patients have cutaneous involvement10. Lesions are divided into two: specific and 
nonspecific skin lesions. 
Skin lesions that contain typical sarcoid granulomas histologically are classified as specific 
lesions. Nonspesific skin lesions are those with nondiagnostic inflamatory patterns ;the most 
common is erythema nodosum. Nonspecific skin lesion lack typical noncaseating 
granulomas5. 
1.5.1 Specific lesions 
The specific lesions of sarcoidosis all contain granulomas histologically, but the clinical 
appearence of the lesions is inconsistent. Specific lesions of sarcoidosis can present as 
macules, papules, plaques, nodules, and ulcerations. The involved skin may be skin colored, 
hyperpigmented, hypopigmented, or violaceous in color. Epidermal changes of the lesions 
may include atrophy, scaling, telengiectasias, or none at all5. Specific sarcoidal lesions most 
often are found on the head and neck, and but may ocur symetrically or asymmetrically on 
any part of the skin and mucosa11. 
1.5.1.1 Papules and plaques 
The most common presentation is papuler form4,5,11.  Papules are eleveted skin lesions less 
than 5mm in size. They have a predilection for the face and especially common around the 
eyes and on the posterior neck. They may be skin colored, hyperpigmented, erythematous, 
hypopigmented, violaceous, but clasically they are described as having a yellow–brown hue 
with an erythematous background. When pressure is applied with a glass slide or a 
dermoscope the erythematous coloration is mitigated and the yellow-brown color (often 
described as the color of apple jelly) can be more easily appreciated4. The apple jelly 
appearence and nodules are not pathognomonic  for sarcoidosis, as other granulomatous 
skin conditions, such as lupus vulgaris may exhibit similiar diascopic properties11.  
The plaques  form of sarcoidosis is rare and involves the extremities, the face and the 
corpus4. Plaques may arise denova or from a confluence of paules.These lesions are larger 
than 5mm in diameter 5. Lupus pernio describes the relatively symmetric, violaceous, 
indurated plaques that ocur on the nose, ear-lobes, cheeks and digits. This clinical variant of 
sarcoidosis is distinctive and has been associated with symmetric involvement. Lupus 
pernio is associated with a higher prevelance of upper respiratory tract disease11. 
 
 
Bezmialem Vakıf University Prof. Dr. Nahide Onsun’s  photograph 
Fig. 1. Violaceous lupus pernio lesion on the nose 
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Bezmialem Vakıf University Prof. Dr. Nahide Onsun’s  photograph 
Fig. 2. Papules and plaques at lower extremity 
 
 
Bezmialem Vakıf University Prof. Dr. Nahide Onsun’s  photograph 
Fig. 3. Papules and plaques 
1.5.1.2 Scar sarcoidosis 
Cutaneous sarcoidosis ocuuring in prior scar tisue, at traumatized areas of skin , or around 
foreign bodies such as tattos is common5. Scars become inflamed and infiltrated with 
sarcoidal granulomas. Inflamation of old scars may paralel or precede systemic disease 
activity11.  The presence of foreign body in granuloma does not exclude sarcoidosis entirely. 
Many cases of scar sarcoidosis are following car accidents in which there is exposure to glass 
and dirt11. 
1.5.1.3 Scalp 
Alopecia occurs with the involvement of the scalp. Scalp sarcoidosis may cause irrversibl 
cicatricial or noncicatricial sarcoidosis. Biopsy shows noncaseating granulomas. Its 
reversibility depends on the degree of the destruction of hair folicules 4,11. 
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Bezmialem Vakıf University Prof. Dr. Nahide Onsun’s  photograph 
Fig. 4. Scalp sarcoidosis 
1.5.1.4  Nail 
Sarcoidal inflammation around the nail matrix or within the distal bones of the digits can 
cause nail abnormalities5. Nail plate deformation and discoloration, clubbing, subungual 
hyperkeratosis may  seen11.  The incidence of hair and nail involvement is very low 4,11. 
1.5.1.5 Mucous membranes 
Sarcoidal granulomas may cause papules and plaques of the mucosal membranes and the 
tongue. Sarcoidosis may cause Mikulicz syndrome11. 
1.5.1.6 Ulcerations 
The cutaneos lesions of sarcoidosis very rarely ulcerate. The most common site is the legs10. 
These lesions may mimic other ulcerative conditions such as venous stasis ulcerations, but 
they have granulomas present histologically5. An ulcerated necrobiosis lipoidica 
diabeticorum must also be considered10. 
1.5.1.7 Subcutaneous nodules 
When the sarcoidal granulomas situated in the addipose tissue the skin induces clinically 
evident subcutaneos nodules and the classic red-brown color may not be seen. Instead the 
overlying skin may be normal or slightly red 5,10. Multipl rather than solitary lesions are 
usually present. This granulomatous panniculitis is known as Darier –Roussy sarcoidosis 5,10. 
1.5.1.8 Angiolupoid sarcoidosis (Brocq and pautrier) 
This form of cronic cutaneous sarcoidosis is features red Brown papules, nodules, an 
plaques with prominent telengiectasies that tend to involve the mid face of the women10. In 
such cases, it is important to consider the rare granuloma eosinophlicum faciei as well as 
pseudolymphoma5. 
1.5.1.9 Macular 
Cutaneos sarcoidosis may present as hypopigmented nonelevted areas. This variant is more 
common in dark skinned patients5. 
1.5.1.10 Additional presentations 
Lots of additional prsentations have been reported. These includes erythroderma12, 
ichtyosiform13, rosacea like type14, psoriasiform15, morpheaform plaques16, lichenoid 
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dermatitis 17, folikülitis like lesions, gyrate erythema, penil and vulvar lesions, palmar 
erythema, discoid lupus like plaques, lower extremity edema, lesions mimicking 
polymorphous light eruption11. 
1.5.2 Nonspecific lesions 
1.5.2.1 Erythema nodosum 
This is the most common nonspecific lesion. In most part of the world , it is necessary to 
exclude sarcoidosis when erythema nodosum is diagnosed in adults10. The lesions of 
erythema nodosum are tender and found predominantly on the lower extremities as well. 
The anterior surface of the lower leg is the most common location5. The presence of bilateral 
hiler adenopathy on chest radiograph with erythema nodosum is known as Löfgren 
syndrome5. 
Other nonspecific lesions  are seen very rare. Prurigo nodules, erythema multiforme, lower 
extremity swelling, Sweet syndrome and pyoderma gangrenosum qualify as nonspecific 
cutaneous sarcoid lesions5,11. 
1.6 Treatment 
The treatment of cutaneous sarcoidosis has been usually derived from agents for pulmonary 
sarcoidosis18. Standard therapeutic interventions for cutaneous sarcoidosis have 
traditionally included topical, intralesional and systemic corticostreoids, antimalarial drugs, 
methotrexate, and combinations of these agents9. 
1.6.1 Corticosteroids 
Corticosteroid are the worldwide accepted standard treatment of sarcoidosis9,18, 19. For the 
patients with mild limited sarcoidosis the treatment may start with using ultrapotent topical 
corticosteroids18. Intralesional injections have been useful for some cases18. The 
concentration of the corticosteroids selected depends on the firmness and size of the lesion, 
but most lesions of sarcoidosis may be treated initially with intralesional triamcinolone at 
concentrations of 3-20 mg/mL repeated  every 4 weeks until the lesions have flattened18. 
Adverse effectas are hypopigmentation and atrophy1,7,8 Systemic corticosteroid theraphy, 
usually delivered orally , should be reserved for severely disfiguring or destructive lesions, 
widespread involvement, or lesions that have proved refractory to localized therapy 19. The 
dosage of prednisone administered ranges from 40 to 80 mg/prednisone administered 
ranges from 40 to 80mg/day and is tapered over weeks to months depending on the clinical 
response 18. 
1.6.2 Antimalarial agents 
The effectiveness of chloroquine and hydroxychloroquine in sarcoidosis  is thougt to be 
related to the ability of these agents to inhibit antigen processing and presentaion by APCs 
to CD4 T cells8. They have antiinflammatory properties 9,18,19. The rate of response appears 
to be higher for cutaneous compared with pulmonary sarcoidosis. These drugs have been 
widely used for cutaneous sarcoidosis18. Maximum oral chloroquine dosage is 3.5 mg/kg/ 
day and hydroxycholoroquine dosage is 6.5mg/kg/day. Lower dosages are effective and 
are preferred to maximal dosing 9,18. The toxicities of antimalarials are nausea, anorexia, 
dizziness, headaches and blurred vision. Bleaching of the hair, agranulocytosis 9,18,19. 
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Agranulocytosis is rare but serious complication of theraphy. Potential ocular efffects are the 
most serious adverse events associated with antimalarial treatment and include the 
development of corneal deposits of central retinopathy18. 
1.6.3 Methotrexate 
Methotrexate is a folate analogue that inhibits dihydrofolate reductase. At high doses 
methotrexate is antiproliferative , in low doses methotrexate has antiinflammatory 
properties 19.  
The dose of methotrexate is varies. In adults , the average starting dosage is 10 to 15mg a 
week 18.Hepatotoxicity is the major long-term effect associated with methotrexate , and 
routine monitoring of alanine aminotransferase, aspartate aminotransferase, alkaline 
phosphatase and serum albumine is recomended9,18,19. While using methotrexate the 
patients must be monitored for neutropenia. Methotrexate is cleared with kidneys ; because 
of this serum creatinine monitoring must be done18. 
Methotrexate is associated with hematologic, gastrointestinal, pulmonary and hepatic 
toxicities 9,18,19. Dose dependent toxicities are mucositis, mouth sores, and nausea. These 
problems can be eliminated by dividing by dividing the dose of methotrexate in half and 
giving oral folate 9,18,19. 
1.6.4 Combination standard theraphy 
Antimalarials and corticosteroids can be used in sequence. By this way complications of the 
long term use can be reduced. Steroids and antinalarials are steroid sparing agents. Both of 
them can be used in place of steroid or in combination with steroids. Combination therapies 
have the advantage of decreasing steroid doses9,18,19 . 
1.6.5 Other therapies 
Pentoxifylline20, tetracyclines21,22, Leflunomide23, Thalidomide24, Infliximab25, 
Chlorambucil26, cyclosporin-A 27, allopurinol 28, laser surgery29 are reported for the 
treatment of sarcoidosis. 
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Sarcoidosis is a type of inflammation that occurs in various locations of the body for no known reason.
Normally, when foreign substances or organisms enter the body, the immune system will fight back by
activating an immune response. Inflammation is a normal part of this immune response, but it should subside
once the foreign antigen is gone. In sarcoidosis, the inflammation persists, and some of the immune cells form
abnormal clumps of tissue called granulomas. The disease can affect any organ in the body, but it is most
likely to occur in the lungs. It can also affect the skin, eyes, liver, or lymph nodes. Although the cause of
sarcoidosis is not known, research suggests that it may be due to an extreme immune response or extreme
sensitivity to certain substances. It also seems to have a genetic component as well, and tends to run in
families. Sarcoidosis most commonly develops in people between 20 and 50 years of age. African Americans
are somewhat more likely to develop sarcoidosis than Caucasians, and females are somewhat more likely to
develop sarcoidosis than males. The symptoms of sarcoidosis depend on the organ involved. This book deals
with the diagnosis and treatment of this mysterious disease of unknown etiology.
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